<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21264" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Eplerenone</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hughes</surname>
            <given-names>Jonathan C.</given-names>
          </name>
          <aff>Saint Thomas Rutherford/Univ. Tennessee</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cassagnol</surname>
            <given-names>Manouchkathe</given-names>
          </name>
          <aff>St. John's University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jonathan Hughes declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Manouchkathe Cassagnol declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21264.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Eplerenone is a medication used in the management and treatment of heart failure with reduced ejection fraction and hypertension. It is in the aldosterone antagonist class of drugs. This activity outlines the indications, action, and contraindications for eplerenone as a valuable agent in managing heart failure and hypertension. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, and monitoring) pertinent for members of the interprofessional team in treating patients with hypertension, heart failure, and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action and administration of eplerenone as regards its use in heart failure and hypertension.</p></list-item><list-item><p>Describe the potential adverse effects of eplerenone.</p></list-item><list-item><p>Outline appropriate monitoring for patients on therapy with eplerenone.</p></list-item><list-item><p>Review interprofessional team strategies for improving care coordination and communication to support optimal medication outcomes for patients prescribed eplerenone.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21264&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21264">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21264.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Eplerenone is classified as an aldosterone antagonist and has been available in the United States since 2002.&#x000a0; Eplerenone&#x02019;s key advantage over its older and less expensive drug in its class, spironolactone, is its increased selectivity for the mineralocorticoid receptor relative to glucocorticoid, progesterone, and androgen receptors.</p>
        <p>Eplerenone is approved by the Food and Drug Administration (FDA) for:</p>
        <list list-type="bullet">
          <list-item>
            <p>The improvement of survival of stable patients with left ventricular (LV) systolic dysfunction (left ventricular ejection fraction less than or equal to 40%) and congestive heart failure (CHF) after an acute myocardial infarction (MI)</p>
          </list-item>
          <list-item>
            <p>Hypertension, alone or combined with other agents.<xref ref-type="bibr" rid="article-21264.r1">[1]</xref><xref ref-type="bibr" rid="article-21264.r2">[2]</xref></p>
          </list-item>
        </list>
        <p>Though the FDA specifies eplerenone&#x02019;s use in heart failure specifically to those status-post myocardial infarctions (MI), it also has off-label use for general heart failure patients with an ejection fraction (EF) less than or equal to35%, especially when they have experienced an adverse effect to spironolactone. The use of eplerenone in these populations has support from the EPHESUS&#x000a0;and EMPHASIS-HF&#x000a0;randomized controlled trials, respectively.<xref ref-type="bibr" rid="article-21264.r3">[3]</xref><xref ref-type="bibr" rid="article-21264.r4">[4]</xref>&#x000a0;</p>
        <p>Concerning its use in hypertension, eplerenone is not a recommended agent for the initial treatment of hypertension.&#x000a0;However,&#x000a0;eplerenone and spironolactone are preferred agents for patients with hypertension due to primary aldosteronism or resistant hypertension. Eplerenone has not been subject to prospective comparisons to spironolactone or other agents in head-to-head trials of resistant hypertension but may be used as an alternative to spironolactone, especially when a patient has experienced antiandrogen adverse effects from spironolactone.</p>
        <p>As an aldosterone antagonist, it is also used off-label to treat primary aldosteronism&#x000a0;and ischemic heart disease.<xref ref-type="bibr" rid="article-21264.r5">[5]</xref><xref ref-type="bibr" rid="article-21264.r6">[6]</xref><xref ref-type="bibr" rid="article-21264.r7">[7]</xref></p>
      </sec>
      <sec id="article-21264.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Aldosterone is a mineralocorticoid that acts on both epithelial (e.g., kidney) and nonepithelial (e.g., heart and blood vessels) receptors to induce sodium and water reabsorption.&#x000a0;In addition to its hypertensive effects, aldosterone is implicated in the progression of myocardial fibrosis, especially following myocardial infarction.&#x000a0;Eplerenone binds to mineralocorticoid receptors competitively, antagonizing aldosterone. Eplerenone&#x02019;s main mechanistic advantage relative to spironolactone is that it has a 100 to 1000-fold lower binding affinity to glucocorticoid, progesterone, and androgen receptors.<xref ref-type="bibr" rid="article-21264.r8">[8]</xref>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-21264.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Eplerenone is only administered orally without regard to food. It achieves peak plasma concentrations 1.5 hours after oral administration with a bioavailability of approximately 70%. Though some sources state that 25 mg of spironolactone is equivalent to 50 mg of eplerenone, there are no head-to-head clinical trials of these agents.&#x000a0;&#x000a0;</p>
        <p>For patients with heart failure, the <italic toggle="yes">2013 ACCF/AHA Guideline for the Management of Heart Failure&#x000a0;</italic>(HF) recommends a starting dose of 25 mg once daily and titrate to a goal dose of 50 mg once daily after four weeks of treatment, potassium less than or equal to 5 mEq/L and adequate renal function (estimated glomerular filtration rate, eGFR greater than or equal to 50 mL/minute/1.73 m^2).<xref ref-type="bibr" rid="article-21264.r9">[9]</xref></p>
        <p>Due to its shorter half-life of 3&#x000a0;to 6 hours, the <italic toggle="yes">2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults</italic>, as well as the 2016 Endocrine Society guideline on primary aldosteronism, admonish that twice-daily dosing may be necessary for optimal effect.<xref ref-type="bibr" rid="article-21264.r10">[10]</xref><xref ref-type="bibr" rid="article-21264.r5">[5]</xref>&#x000a0;</p>
        <p>Renal dose adjustments are necessary with the use of eplerenone as described below:</p>
        <p>For hypertension (manufacturer's labeling)</p>
        <list list-type="bullet">
          <list-item>
            <p>Contraindicated in creatinine clearance (CrCl)&#x000a0;less than 50 mL/minute or serum creatinine&#x000a0;greater than 2mg/dL (males) or over 1.8 mg/dL (females)</p>
          </list-item>
          <list-item>
            <p>HF, post-MI (manufacturer's labeling)</p>
          </list-item>
          <list-item>
            <p>Use with caution in CrCl 31 to 50 mL/minute or serum creatinine&#x000a0;exceeding 2mg/dL (males) or 1.8 mg/dL (females)</p>
          </list-item>
          <list-item>
            <p>Contraindicated in CrCl less than or equal to 30 mL/minute</p>
          </list-item>
        </list>
        <p>According to the <italic toggle="yes">2013 ACCF/AHA Guideline for the Management of Heart Failure</italic> recommendation for HF (including post-MI)<xref ref-type="bibr" rid="article-21264.r9">[9]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>eGFR 30 to 49 mL/min/1.73m2 initiate a starting dose of 25 mg once every other day and titrate to a goal dose of 25 mg once daily after four weeks of treatment and potassium less than or equal to 5 mEq/L</p>
          </list-item>
          <list-item>
            <p>Contraindicated in eGFR&#x000a0;below 30 mL/min</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21264.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Hyperkalemia is by far the most common adverse effect of eplerenone. Clinical trial experience indicates an approximately 1.5&#x000a0;to 2.0 fold risk of hyperkalemia, with a number needed to harm ranging from 23 to 62. While serious hyperkalemia (greater than or equal to 6 mEq/L) was more common in both the EMPHASIS and EPHESUS trials, the adverse effect&#x000a0;was usually manageable&#x000a0;by reducing the dose or temporarily discontinuing the drug. In contrast, hypokalemia&#x02014;which correlates with an increased risk of death from any cause among heart failure patients&#x02014;was significantly reduced.&#x000a0;Though serum creatinine may rise on eplerenone, the EMPHASIS-HF trial found no increased risk of renal failure.</p>
        <p>Notably absent as a side effect is gynecomastia, which occurred in about 9% of the patients taking spironolactone in the RALES trial.<xref ref-type="bibr" rid="article-21264.r11">[11]</xref>&#x000a0;In both the EMPHASIS-HF and EPHESUS trials, gynecomastia was no more common in patients taking eplerenone compared to placebo. Indeed, researchers have used eplerenone to reverse the effects of spironolactone-induced gynecomastia in small trials of patients with cirrhosis or primary hyperaldosteronism.<xref ref-type="bibr" rid="article-21264.r12">[12]</xref><xref ref-type="bibr" rid="article-21264.r13">[13]</xref> &#x000a0;</p>
      </sec>
      <sec id="article-21264.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Clinicians should not start eplerenone therapy in patients with potassium greater than 5.5 mEq/L or a CrCl less than 30 mL/min, as these increase the risk of serious hyperkalemia. Since eplerenone metabolism is via CYP3A4, potent CYP3A4 inhibitors (including specific protease inhibitors, azole antifungals, and clarithromycin) may increase eplerenone to unsafe blood concentrations.&#x000a0;</p>
        <p>Of note, when used for hypertension, more stringent contraindications are applied:</p>
        <list list-type="bullet">
          <list-item>
            <p>Types 2 diabetes with microalbuminuria</p>
          </list-item>
          <list-item>
            <p>Serum creatinine over 2.0 mg/dL in males and 1.8 mg/dL in females or a CrCl below 50mL/min</p>
          </list-item>
          <list-item>
            <p>Concomitant use of potassium supplementation or potassium-sparing diuretics</p>
          </list-item>
        </list>
        <p>Since Addison disease characteristically demonstrates an aldosterone deficiency, eplerenone is also contraindicated in these patients.</p>
      </sec>
      <sec id="article-21264.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Though eplerenone's indications include the treatment of hypertension, its effects on blood pressure likely depend on the population studied.&#x000a0; For example, in the EMPHASIS-HF study, systolic blood pressure decreased by a mean of 2.2 mmHg relative to the placebo group.&#x000a0; In contrast, systolic blood pressure <italic toggle="yes">increased</italic> in the EPHESUS trial by 3 mmHg relative to the placebo group (presumably), reflecting the improved recovery of cardiac output).</p>
        <p>Serum creatinine and potassium require monitoring for all indications, but patients with HF are most vulnerable to hyperkalemia.&#x000a0; To this end, the <italic toggle="yes">2013 ACCF/AHA Guideline for the Management of Heart Failure</italic> recommends serum potassium, and renal function check occurs on the following schedule after initiation: 3 days, one week,&#x000a0;monthly for the first three months of therapy and every three months thereafter.&#x000a0;If either of these parameters worsens, hold eplerenone until the potassium is less than 5 mEq/L and consider restarting with a reduced dose after confirming resolution of the metabolic abnormality for at least 72 hours.<xref ref-type="bibr" rid="article-21264.r9">[9]</xref></p>
      </sec>
      <sec id="article-21264.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There are no known overdose reports of eplerenone, but the most likely manifestations of overdose would be hypotension or hyperkalemia.&#x000a0; Researchers have not observed any lethality in overdose studies in mice, rats, or dogs, but dogs demonstrated emesis, salivations, and tremors at a concentration 41 times the human therapeutic concentration of eplerenone.&#x000a0;These progressed to sedation and convulsions at higher exposures.&#x000a0;&#x000a0;</p>
        <p>Should toxicity occur, eplerenone binds extensively to charcoal but is not removable by hemodialysis.&#x000a0;There is no specific antidote to eplerenone; thus, supportive treatment for hypotension or hyperkalemia would be necessary. Eplerenone is not dialyzable.</p>
      </sec>
      <sec id="article-21264.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Over two decades of experience have demonstrated the effect of aldosterone antagonists on survival and hospitalizations in heart failure patients with reduced ejection fraction.&#x000a0;Therefore, one of the chief duties of the interprofessional healthcare team is to ensure that such patients receive aldosterone antagonists, including eplerenone, when appropriate, as part of guideline-directed medical therapy.&#x000a0;Pharmacists should review the dose, check for drug interactions, and provide patient education. Specialty trained nurses such are cardiology nurses monitor patients, provide education, and report status changes to the team. These examples of interprofessional interaction and collaboration should lead to more effective use of eplerenone. [Level 5]</p>
        <p>As regards safety, regular lab monitoring is of paramount importance for patients taking eplerenone. Following the release of the RALES trial, hospitalizations and deaths secondary to serious hyperkalemia significantly increased.<xref ref-type="bibr" rid="article-21264.r14">[14]</xref>&#x000a0;Researchers postulated this to be due to the increased use of spironolactone without the close lab monitoring utilized during the clinical trial.&#x000a0;Since patients with heart failure are often co-managed by primary care clinicians and specialists, it is easy to become siloed and assume the other clinician is monitoring therapy.&#x000a0;When used for patients who have experienced gynecomastia on spironolactone, the patient requires monitoring to resolve this adverse effect.</p>
        <p>Finally, though eplerenone is now generic, it is more expensive than spironolactone.</p>
      </sec>
      <sec id="article-21264.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21264&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21264">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21264/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21264">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21264.s11">
        <title>References</title>
        <ref id="article-21264.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2018</year>
            <month>May</month>
            <day>15</day>
            <volume>71</volume>
            <issue>19</issue>
            <fpage>e127</fpage>
            <page-range>e127-e248</page-range>
            <pub-id pub-id-type="pmid">29146535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21264.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krasi&#x00144;ska</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cofta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Szczepaniak-Chiche&#x00142;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rzymski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Trafas</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Paluszkiewicz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tykarski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Krasi&#x00144;ski</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>The Effects of Eplerenone on the Circadian Blood Pressure Pattern and Left Ventricular Hypertrophy in Patients with Obstructive Sleep Apnea and Resistant Hypertension-A Randomized, Controlled Trial.</article-title>
            <source>J Clin Med</source>
            <year>2019</year>
            <month>Oct</month>
            <day>13</day>
            <volume>8</volume>
            <issue>10</issue>
            <pub-id pub-id-type="pmid">31614891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21264.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pitt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Remme</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zannad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Neaton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Roniker</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bittman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hurley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kleiman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gatlin</surname>
                <given-names>M</given-names>
              </name>
              <collab>Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators</collab>
            </person-group>
            <article-title>Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.</article-title>
            <source>N Engl J Med</source>
            <year>2003</year>
            <month>Apr</month>
            <day>03</day>
            <volume>348</volume>
            <issue>14</issue>
            <fpage>1309</fpage>
            <page-range>1309-21</page-range>
            <pub-id pub-id-type="pmid">12668699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21264.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zannad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Krum</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>van Veldhuisen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Swedberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pocock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Pitt</surname>
                <given-names>B</given-names>
              </name>
              <collab>EMPHASIS-HF Study Group</collab>
            </person-group>
            <article-title>Eplerenone in patients with systolic heart failure and mild symptoms.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>Jan</month>
            <day>06</day>
            <volume>364</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-21</page-range>
            <pub-id pub-id-type="pmid">21073363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21264.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Funder</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Mantero</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Reincke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shibata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Stowasser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>WF</given-names>
              </name>
            </person-group>
            <article-title>The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2016</year>
            <month>May</month>
            <volume>101</volume>
            <issue>5</issue>
            <fpage>1889</fpage>
            <page-range>1889-916</page-range>
            <pub-id pub-id-type="pmid">26934393</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21264.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prejean</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Din</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reyes</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hage</surname>
                <given-names>FG</given-names>
              </name>
            </person-group>
            <article-title>Guidelines in review: Comparison of the 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes and the 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.</article-title>
            <source>J Nucl Cardiol</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>769</fpage>
            <page-range>769-776</page-range>
            <pub-id pub-id-type="pmid">29230658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21264.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Gara</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Ascheim</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>de Lemos</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ettinger</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fesmire</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Linderbaum</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Newby</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Ornato</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ou</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Radford</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Tamis-Holland</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Tommaso</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>DX</given-names>
              </name>
            </person-group>
            <article-title>2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2013</year>
            <month>Jan</month>
            <day>29</day>
            <volume>61</volume>
            <issue>4</issue>
            <fpage>e78</fpage>
            <page-range>e78-e140</page-range>
            <pub-id pub-id-type="pmid">23256914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21264.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Struthers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Krum</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>A comparison of the aldosterone-blocking agents eplerenone and spironolactone.</article-title>
            <source>Clin Cardiol</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>153</fpage>
            <page-range>153-8</page-range>
            <pub-id pub-id-type="pmid">18404673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21264.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Jessup</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Geraci</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Horwich</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Januzzi</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Kasper</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Masoudi</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>McBride</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Riegel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sam</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Wilkoff</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.</article-title>
            <source>Circulation</source>
            <year>2013</year>
            <month>Oct</month>
            <day>15</day>
            <volume>128</volume>
            <issue>16</issue>
            <fpage>1810</fpage>
            <page-range>1810-52</page-range>
            <pub-id pub-id-type="pmid">23741057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21264.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>1269</fpage>
            <page-range>1269-1324</page-range>
            <pub-id pub-id-type="pmid">29133354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21264.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pitt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zannad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Remme</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Cody</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Castaigne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Palensky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wittes</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.</article-title>
            <source>N Engl J Med</source>
            <year>1999</year>
            <month>Sep</month>
            <day>02</day>
            <volume>341</volume>
            <issue>10</issue>
            <fpage>709</fpage>
            <page-range>709-17</page-range>
            <pub-id pub-id-type="pmid">10471456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21264.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dimitriadis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Papadopoulos</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mimidis</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Eplerenone reverses spironolactone-induced painful gynaecomastia in cirrhotics.</article-title>
            <source>Hepatol Int</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>738</fpage>
            <page-range>738-9</page-range>
            <pub-id pub-id-type="pmid">21484105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21264.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karagiannis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tziomalos</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kakafika</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Florentin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Athyros</surname>
                <given-names>VG</given-names>
              </name>
            </person-group>
            <article-title>Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>293</fpage>
            <pub-id pub-id-type="pmid">17018542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21264.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Juurlink</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Mamdani</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Kopp</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Austin</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Laupacis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Redelmeier</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.</article-title>
            <source>N Engl J Med</source>
            <year>2004</year>
            <month>Aug</month>
            <day>05</day>
            <volume>351</volume>
            <issue>6</issue>
            <fpage>543</fpage>
            <page-range>543-51</page-range>
            <pub-id pub-id-type="pmid">15295047</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
